Farmak International Secures Over 50 UK Marketing Authorisations in 2025
In 2025, Farmak International reached a significant regulatory milestone in the UK, with its local team securing over 50 Marketing Authorisations across a diverse portfolio of medicines.
The approvals represent a concentrated phase of regulatory execution and further strengthen the portfolio foundation, supporting Farmak International’s long-term UK and Ireland strategy.
Building a broad portfolio base
The newly authorised medicines span primary care, hospital, and specialist settings, reflecting a deliberate focus on portfolio breadth and structural readiness.
The approvals cover therapies used in:
• Anaesthesia, critical care and injectable therapies
• Cardiovascular care
• Central nervous system disorders
• Diagnostic imaging
• Metabolic and endocrine conditions
• Pain management and anti-inflammatory treatment
• Women’s health
Across these areas, multiple strengths and pharmaceutical forms were authorised, supporting flexible portfolio planning and continuity across different treatment settings.
Regulatory execution as a partner capability
Completing this volume of approvals within a single year highlights the UK team’s ability to manage parallel submissions and complex regulatory pathways under MHRA procedures. The 2025 outcomes reflect intensive regulatory coordination, expanding the authorised base, while complementing products already present on the UK market.
The accomplishments of the UK regulatory affairs team is reflective of its strategic planning capabilities and close collaboration with internal regulatory expertise, as well as with external partners. With 40+ years of combined regulatory knowledge and experience across the team, it is the complementary strengths of the individual team members that drive its success. Also attributable are the robust interdepartmental synergies, allowing for rapid response to both legislative and product launch requirements. I am extremely proud to be part of Farmak International and to manage this team. I look forward to supporting its continued growth
Lisa Taylor Director of Medical & Regulatory Affairs, UK/IE
Perspective for partners
For partners active in or entering the UK market, the 2025 approvals provide a clear view of the scope and maturity of the authorised portfolio, as well as the regulatory capabilities supporting it. The breadth achieved across therapeutic areas allows for different collaboration approaches to be considered over time, aligned with market needs and partner priorities.
The 2025 Marketing Authorisations build on recent UK milestones, including the launch of an anaesthetic product for hospital use in the UK market earlier this year, reinforcing the company’s ongoing, stepwise expansion of its UK presence.
